Status
Conditions
Study type
Funder types
Identifiers
About
The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality. The diagnosis of NASH requires liver biopsy that cannot be used for the screening of the disease.
The broad prevalence of the disease limits also the generalization of liver biopsy even for diagnosis. There is an urgent need for the use and the validation of liver diagnosis biomarkers for the diagnosis of NASH.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with 1 at least of the following metabolic criteria :
Indication of NAFLD evaluation
Patients written consent
Affiliated to a social insurance
Exclusion criteria
Loading...
Central trial contact
Guillaume Lassailly, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal